• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Digoxin-Zori
    / Teva


    Active Ingredient
    Digoxin 0.25 mg

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Tablets

    40 X 0.25 mg

    full basket chart 682 4118

    Related information


    Dosage

    See prescribing information for full details.


    Indications

    Congestional heart failure, atrial flutter, paroxysmal atrial tachycardia.


    Contra-Indications

    Known hypersensitivity. Ventricular fibrillation.
    See prescribing information for full details.


    Special Precautions

    Many of the arrhythmias for which digoxin is indicated closely resemble those reflecting digoxin intoxication. Anorexia, nausea, vomiting and arrhythmias may accompany heart failure or may be indicative of digoxin intoxication. Electrical conversion of arrhythmias may require reduction of dosage of digoxin, to avoid induction of ventricular arrhythmias. However, the consequences of a rapid increase in ventricular response to atrial fibrillation should be considered if digoxin is withheld 1-2 days prior to cardioversion. Patients still experiencing effects from previous digitalis preparations, and in the presence of multiple ventricular extrasystoles or heart block. Patients with incomplete atrioventricular (AV) block, especially those subject to Stokes-Adams attacks, may develop advanced or complete heart block if digoxin is administered. Patients with acute myocardial infarction, severe pulmonary disease, rheumatic carditis, or advanced heart failure. If a therapeutic trial does not result in improvement, the drug should be discontinued. Patients with chronic constrictive pericarditis, patients with Wolff-Parkinson-White syndrome. The presence of acute glomerulonephritis accompanied by CHF requires extreme care in digitalization. Pregnancy and lactation, pediatrics, elderly, hypokalemia. Calcium i.v. should not be administered to patients receiving digoxin. Hypomagnesemia. The plasma half-life of digoxin is inversely related to thyroid status. Atrial arrhythmias associated with hypermetabolic states are particularly resistant to digoxin treatment. Patients with renal impairment.
    See prescribing information for full details.


    Side Effects

    Anorexia, nausea, vomiting and diarrhea are the most common early symptoms of overdose. Uncontrolled heart failure may also produce such symptoms. Visual disturbances, headache, weakness, apathy, drowsiness, mental depression, confusion, disorientation, seizures, EEG abnormalities and delirium, muscular weakness, arrhythmias.
    See prescribing information for full details.


    Drug interactions

    See prescribing information for full details.


    Manufacturer
    Teva Pharmaceutical Industries Ltd, Israel
    CLOSE